Marc Hummersone

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie et al. · Molecular Cancer Therapeutics · 2009 · 389 citations · Full text

Medicine, Cancer Biology, Oncology +14

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Kurt G. Pike, Karine Malagu, Marc Hummersone et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 206 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Enantioselective Formal Total Synthesis of the Antitumor Macrolide Bryostatin 7

Soraya Manaviazar, Mark Frigerio, Gurpreet Singh Bhatia et al. · Organic Letters · 2006 · 83 citations

Pharmacy, Chemistry, Medicinal Chemistry +9

Pyranone, Thiopyranone, and Pyridone Inhibitors of Phosphatidylinositol 3-Kinase Related Kinases. Structure−Activity Relationships for DNA-Dependent Protein Kinase Inhibition, and Identification of the First Potent and Selective Inhibitor of the Ataxia Telangiectasia Mutated Kinase

Jonathan J. Hollick, Laurent Rigoreau, Céline Cano et al. · Journal of Medicinal Chemistry · 2007 · 82 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14